Investigation on autologous mesenchymal stem cell transplantation in diabetic nephrophaty (type one)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201111291414N28

Enrollment

Registered

2012-07-29

Start date

2012-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Nephropathy (type 1). Glomerular disorders in diabetes mellitus

Interventions

Injection of autologous mesenchymal stem cell

Injection of autologous mesenchymal stem cell.

Treatment - Other

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. signing informed consent 2. People with diabetes type one with at least 10 years duration 3. age 18-40 years 4. Diabetic nephropathy diagnosed by nephrologists 5. HbA1c = 7.5% (blood glucose is controlled at least for one month) Exclusion criteria: 1. acute vascular inflammation 2. acute thrombosis (three months) 3. recent bleeding in the retina (the last three months) 4. pulmonary hypertension 5. liver disease 6. tumors in bone marrow or any malignancy is diagnosed 7. infectious diseases 8. mental illness 9. generalized edema 10. malignancy 11. pregnancy 12. Diastolic blood pressure =110 13. Cigar Smoker

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
GFR. Timepoint: Before intervention(time 0) and 4,12,24,48,96 weeks after cell infusion. Method of measurement: using MDRD and Cockroft-Gault formula-ml/min/1.73square meter.;Albumin/Creatinine ratio. Timepoint: Before intervention(time 0) and 4,12,24,48,96 weeks after cell infusion. Method of measurement: mg/mmol.	—

Secondary

Measure	Time frame
C-peptide. Timepoint: Before intervention(time 0) and 4,12,24,48,96 weeks after cell infusion. Method of measurement: ng/ml.;Cr. Timepoint: Before intervention(time 0) and 4,12,24,48,96 weeks after cell infusion. Method of measurement: mg/dl.;BUN. Timepoint: Before intervention(time 0) and 4,12,24,48,96 weeks after cell infusion. Method of measurement: mg/dl.;HbA1c. Timepoint: Before intervention(time 0) and 4,12,24,48,96 weeks after cell infusion. Method of measurement: %.;FBS. Timepoint: Before intervention(time 0) and 4,12,24,48,96 weeks after cell infusion. Method of measurement: mg/dl.	—

Measure

Time frame

C-peptide. Timepoint: Before intervention(time 0) and 4,12,24,48,96 weeks after cell infusion. Method of measurement: ng/ml.;Cr. Timepoint: Before intervention(time 0) and 4,12,24,48,96 weeks after cell infusion. Method of measurement: mg/dl.;BUN. Timepoint: Before intervention(time 0) and 4,12,24,48,96 weeks after cell infusion. Method of measurement: mg/dl.;HbA1c. Timepoint: Before intervention(time 0) and 4,12,24,48,96 weeks after cell infusion. Method of measurement: %.;FBS. Timepoint: Before intervention(time 0) and 4,12,24,48,96 weeks after cell infusion. Method of measurement: mg/dl.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026